Galmed Pharmaceuticals Ltd.
(NASDAQ : GLMD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
-1.00%171.250.4%$136.39m
JAZZJazz Pharmaceuticals Plc
-0.35%176.492.2%$114.93m
SAGESAGE Therapeutics, Inc.
-0.04%168.569.6%$110.81m
PRGOPerrigo Co. Plc
0.16%75.956.7%$91.16m
ENDPEndo International Plc
-0.62%11.158.9%$71.94m
MNKMallinckrodt Plc
-1.03%21.6821.1%$69.05m
ICPTIntercept Pharmaceuticals, Inc.
-2.02%93.8021.8%$66.13m
ZGNXZogenix, Inc.
-0.93%58.4011.9%$66.12m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-1.61%146.226.8%$62.62m
CTLTCatalent Inc
1.48%43.982.6%$61.16m
MDCOMedicines Company
-0.70%39.8021.8%$38.54m
UTHRUnited Therapeutics Corporation
0.76%125.0314.4%$38.37m
SUPNSupernus Pharmaceuticals, Inc.
1.15%54.886.3%$36.47m
PTLAPortola Pharmaceuticals, Inc.
0.05%39.947.7%$34.31m
ICLRICON Plc
1.29%140.144.2%$31.48m

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.